Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIM1 | P11309 | 1/20 | 0.34 |
| ▸ | PIM3 | Q86V86 | 1/20 | 0.34 |
| ▸ | PIM2 | Q9P1W9 | 1/20 | 0.34 |
| ▸ | CA12 | O43570 | 1/20 | 0.32 |
| ▸ | CA9 | Q16790 | 1/20 | 0.32 |
| ▸ | CLK4 | Q9HAZ1 | 2/20 | 0.30 |
| ▸ | DYRK1B | Q9Y463 | 2/20 | 0.30 |
| ▸ | FYN | P06241 | 1/20 | 0.30 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.30 |
| ▸ | PIK3R1 | P27986 | 1/20 | 0.30 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.30 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.30 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.30 |
| ▸ | TYRO3 | Q06418 | 1/20 | 0.30 |
| ▸ | NTRK2 | Q16620 | 1/20 | 0.30 |
| ▸ | PARP1 | P09874 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12240927 | 0.76 | PNMT (0.39) | PIM1PIM3PIM2CA12CA9 | |
| SCHEMBL164372 | 0.72 | PNMT (0.36) | PIM1PIM3PIM2CA12CA9 | |
| SCHEMBL21152275 | 0.71 | CDK1 (0.37) | PIM1PIM3PIM2CA12CA9 | |
| SCHEMBL21152997 | 0.71 | TMIGD3 (0.35) | PIM1PIM3PIM2CA12CA9 | |
| SCHEMBL12219894 | 0.71 | PRKDC (0.36) | PIM1PIM3PIM2CA12CA9 | |
| SCHEMBL25412641 | 0.71 | PNMT (0.44) | PIM1PIM3PIM2CA12CA9 | |
| SCHEMBL161393 | 0.69 | CA12 (0.33) | PIM1PIM3PIM2CA12CA9 | |
| SCHEMBL25415312 | 0.69 | CA12 (0.33) | PIM1PIM3PIM2CA12CA9 | |
| SCHEMBL21153118 | 0.64 | DAO (0.38) | — | |
| SCHEMBL22870125 | 0.62 | TTR (0.35) | PIM1PIM3PIM2CA12CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3735404-B1 | ASK1 INHIBITOR COMPOUNDS AND USES THEREOF | SEAL ROCK THERAPEUTICS INC (US) | 2023-11-29 | — | — | EP | disclosed |
| US-20210213006-A1 | METHODS OF TREATING NEURODEGENERATIVE DISEASES | Seal Rock Therapeutics, Inc. | 2021-07-15 | — | — | US | disclosed |
| WO-2020046975-A1 | METHODS OF TREATING NEURODEGENERATIVE DISEASES | Seal Rock Therapeutics, Inc. (US) | 2020-03-05 | — | — | WO | disclosed |
| WO-2019136025-A1 | ASK1 INHIBITOR COMPOUNDS AND USES THEREOF | Seal Rock Therapeutics, Inc. (US) | 2019-07-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210213006-A1 | METHODS OF TREATING NEURODEGENERATIVE DISEASES | SNCA, MAPT, HTT | PIM1 2542/4885PIM3 2861/4885PIM2 3263/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.